Tags

Type your tag names separated by a space and hit enter

Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues.
Clin Cancer Res. 2005 Jun 15; 11(12):4331-7.CC

Abstract

Activation of telomerase, a key event during immortalization and malignant transformation, requires expression of the telomerase reverse transcriptase (hTERT). Consistently, lack of telomerase activity and hTERT expression occurs in most normal human somatic cells. However, it has been observed that both normal and cancerous renal tissues express hTERT whereas only the latter exhibits telomerase activity. The mechanism underlying the dissociation between hTERT expression and telomerase activity is unclear. In the present study, we examined telomerase activity and alternative splicing of hTERT transcripts in renal cell carcinoma (RCC) specimens and adjacent normal tissues from 33 patients with RCC. Telomerase activity was detectable in 27 of 33 (82%) RCC samples but none in their normal counterparts. Thirty-two of 33 tumors expressed overall hTERT mRNA and 27 of them contained full-length hTERT transcripts, all with telomerase activity. Although 42% (14 of 33) of normal renal samples expressed hTERT mRNA, none of them had full-length hTERT transcripts, coinciding with lack of telomerase activity. The presence of full-length hTERT mRNA and telomerase activity was significantly associated with c-MYC induction. In tumors, absence of full-length hTERT mRNA or telomerase activity defines a subgroup of nonmetastatic, early-stage RCCs. Taken together, telomerase repression in normal renal tissues is attributed to the absence of full-length hTERT transcripts, whereas telomerase activation is achieved via induction of or switch to expression of full-length hTERT mRNA during the oncogenic process of kidneys, and associated with aggressive RCCs.

Authors+Show Affiliations

Division of Urology, Department of Surgery, Karolinska University Hospital, Stockholm, Sweden.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15958614

Citation

Fan, Yidong, et al. "Differential Expression of Full-length Telomerase Reverse Transcriptase mRNA and Telomerase Activity Between Normal and Malignant Renal Tissues." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol. 11, no. 12, 2005, pp. 4331-7.
Fan Y, Liu Z, Fang X, et al. Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues. Clin Cancer Res. 2005;11(12):4331-7.
Fan, Y., Liu, Z., Fang, X., Ge, Z., Ge, N., Jia, Y., Sun, P., Lou, F., Björkholm, M., Gruber, A., Ekman, P., & Xu, D. (2005). Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 11(12), 4331-7.
Fan Y, et al. Differential Expression of Full-length Telomerase Reverse Transcriptase mRNA and Telomerase Activity Between Normal and Malignant Renal Tissues. Clin Cancer Res. 2005 Jun 15;11(12):4331-7. PubMed PMID: 15958614.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues. AU - Fan,Yidong, AU - Liu,Zhaoxu, AU - Fang,Xiaolei, AU - Ge,Zheng, AU - Ge,Nan, AU - Jia,Yong, AU - Sun,Peng, AU - Lou,Fenglan, AU - Björkholm,Magnus, AU - Gruber,Astrid, AU - Ekman,Peter, AU - Xu,Dawei, PY - 2005/6/17/pubmed PY - 2005/8/18/medline PY - 2005/6/17/entrez SP - 4331 EP - 7 JF - Clinical cancer research : an official journal of the American Association for Cancer Research JO - Clin Cancer Res VL - 11 IS - 12 N2 - Activation of telomerase, a key event during immortalization and malignant transformation, requires expression of the telomerase reverse transcriptase (hTERT). Consistently, lack of telomerase activity and hTERT expression occurs in most normal human somatic cells. However, it has been observed that both normal and cancerous renal tissues express hTERT whereas only the latter exhibits telomerase activity. The mechanism underlying the dissociation between hTERT expression and telomerase activity is unclear. In the present study, we examined telomerase activity and alternative splicing of hTERT transcripts in renal cell carcinoma (RCC) specimens and adjacent normal tissues from 33 patients with RCC. Telomerase activity was detectable in 27 of 33 (82%) RCC samples but none in their normal counterparts. Thirty-two of 33 tumors expressed overall hTERT mRNA and 27 of them contained full-length hTERT transcripts, all with telomerase activity. Although 42% (14 of 33) of normal renal samples expressed hTERT mRNA, none of them had full-length hTERT transcripts, coinciding with lack of telomerase activity. The presence of full-length hTERT mRNA and telomerase activity was significantly associated with c-MYC induction. In tumors, absence of full-length hTERT mRNA or telomerase activity defines a subgroup of nonmetastatic, early-stage RCCs. Taken together, telomerase repression in normal renal tissues is attributed to the absence of full-length hTERT transcripts, whereas telomerase activation is achieved via induction of or switch to expression of full-length hTERT mRNA during the oncogenic process of kidneys, and associated with aggressive RCCs. SN - 1078-0432 UR - https://www.unboundmedicine.com/medline/citation/15958614/Differential_expression_of_full_length_telomerase_reverse_transcriptase_mRNA_and_telomerase_activity_between_normal_and_malignant_renal_tissues_ L2 - http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=15958614 DB - PRIME DP - Unbound Medicine ER -